A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.

Date publication

novembre 2020

Journal

British journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EBERST Lauriane

Tous les auteurs :
Le Tourneau C, Delord JP, Kotecki N, Borcoman E, Gomez-Roca C, Hescot S, Jungels C, Vincent-Salomon A, Cockenpot V, Eberst L, Molé A, Jdey W, Bono F, Trochon-Joseph V, Toussaint H, Zandanel C, Adamiec O, de Beaumont O, Cassier PA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32839491

Résumé

AsiDNA, a first-in-class oligonucleotide-mimicking double-stranded DNA breaks, acts as a decoy agonist to DNA damage response in tumour cells. It also activates DNA-dependent protein kinase and poly (adenosine diphosphate [ADP]-ribose) polymerase enzymes that induce phosphorylation of H2AX and protein PARylation.

Mots clés

Administration, Intravenous, Adult, Aged, Belgium, Cholesterol, administration & dosage, DNA, administration & dosage, DNA Repair, drug effects, Disease Progression, Dose-Response Relationship, Drug, Female, France, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, drug therapy

Référence

Br J Cancer. 2020 11;123(10):1481-1489